ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors.

According to CEO Sang Hoon Lee, ABL001 was the first bispecific antibody to enter the clinic in South Korea; the compound is in Phase I testing for colon and ovarian cancer, as well as a third undisclosed indication. In 2Q19, ABL plans to complete Phase Ia testing of ABL001 and to start pan-Asian Phase Ib trials in combination with chemotherapy. ...